Swift Biosciences, Inc.: Series A $3M

Posted in I - Series A, Q - 3Q10, R - MID WEST, X - Reagent, XX - MI

Swift Biosciences (Ann Arbor, MI) a development-stage company focused on molecular biology reagents for R&D and diagnostics, closed a $3M Series A financing. Participants include DFJ Mercury.

Stemgent, Inc.: Series B $5.6M

Posted in I - Series B, Q - 2Q10, R - NORTH EAST, X - Reagent, X - Stem Cell, XX - MA

Stemgent (Cambridge, MA) a commercial-stage supplier of stemcell related reagents and tools, closed a $5.6M Series B financing. Participants include HealthCare Ventures and Morgenthaler Ventures.

OriGene Technologies, Inc.: Series B $16M

Posted in I - Series B, Q - 1Q10, R - MID ATLANTIC, X - Antibody, X - Reagent, XX - MD

OriGene Technologies (Rockville, MD) a commercial-stage gene-based reagent product company focused on cDNA and shRNA clone collections, purified human proteins, monoclonal antibodies, human tissues, multiplex assay products, antigen standards and IHC slides, closed a $16M Series B financing. Participants include IDG-Accel, SBI Ven Capital, TH Venture Capital Enterprise, Zero2IPO, Morningside and President International Development Corp..

Stemgent, Inc.: Series A $14M

Posted in I - Series A, Q - 1Q09, R - NORTH EAST, X - Reagent, X - Stem Cell, XX - MA

Stemgent (Cambridge, MA) a commercial-stage supplier of stemcell related reagents and tools, closed a $14M Series A financing. Participants include HealthCare Ventures and Morgenthaler Ventures.

China Diagnostics Medical Corp Ltd.: Series B $16.5M

Posted in I - Series B, Q - 4Q08, R - INTERNATIONAL, X - Diagnostic, X - Reagent

China Diagnostics Medical (International) a diagnostics company specializing on development, manufacturing and distribution of in vitro diagnostic reagents and instruments, closed a $16.5 Series B financing. Participants include China Healthcare Partnership, WI Harper, Siemens Venture Capital and Softbank China Venture Capital.

Promosome, Inc.: Series B $9.6M

Posted in I - Series B, Q - 4Q08, R - NORTH EAST, X - Diagnostic, X - Reagent

Promosome (NY, NY) an early-stage platform reagents and diagnostics biotechnology company closed a $9.6M Series B financing. Participants NGN.

BAC, BV: Series B $1.9M

Posted in I - Series B, Q - 3Q08, R - INTERNATIONAL, X - Antibody, X - Reagent

BAC (Netherlands) early-stage company focused on developing purification ligands and immobilized purification products, closed a $1.9M Series B financing. Participants include Unilever Ventures, FF&P Private Equity, Fleming Family & Partners.

ForteBio, Inc: Series C $25M

Posted in I - Series C, Q - 3Q08, R - WEST, X - Reagent

ForteBio (Menlo Park, CA) supplier of label-free technology for the development of life science and pharmaceutical products, closed a $25M Series C financing. Participants include OrbiMed Advisors, MPM Capital, Alloy Ventures, Latterell Venture Partners, The Vertical Group and Versant Ventures.

HandyLab, Inc.: Series D $19.2M

Posted in I - Series D, Q - 3Q08, R - MID WEST, X - Device (Diagnostic), X - Reagent

HandyLab (Ann Arbor, MI) commercial-stage developer of nucleic acid testing devices, closed a $19.2M Series D financing. Participants include Dow Ventures, Lurie Investments, EDF Ventures, Ardesta, Arboretum Ventures and Pfizer Strategic Investments.

VisEn Medical, Inc.: Series B $12M

Posted in I - Series B, Q - 2Q08, R - NORTH EAST, X - Biomarker, X - Imaging, X - Reagent

VisEn Medical (Woburn, MA) commercial-stage company focused on fluorescence in vivo imaging, closed a $5M Series B financing. Participants include Merck Capital Ventures and Flagship Ventures.

« Previous Entries

to top of page...